These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 17199737

  • 1. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
    Zuo H, Nakamura Y, Yasuoka H, Zhang P, Nakamura M, Mori I, Miyauchi A, Kakudo K.
    Pathol Int; 2007 Jan; 57(1):12-20. PubMed ID: 17199737
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
    Baitei EY, Zou M, Al-Mohanna F, Collison K, Alzahrani AS, Farid NR, Meyer B, Shi Y.
    J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
    [Abstract] [Full Text] [Related]

  • 5. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.
    Cancer; 2005 Jun 01; 103(11):2261-8. PubMed ID: 15880523
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
    Vasil'ev EV, Rumiantsev PO, Saenko VA, Il'in AA, Poliakova EIu, Nemtsova MV, Zaletaev DV.
    Mol Biol (Mosk); 2004 Jun 01; 38(4):642-53. PubMed ID: 15456136
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
    Santarpia L, Myers JN, Sherman SI, Trimarchi F, Clayman GL, El-Naggar AK.
    Cancer; 2010 Jun 15; 116(12):2974-83. PubMed ID: 20564403
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
    Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P.
    Cancer Res; 2009 Nov 01; 69(21):8317-25. PubMed ID: 19861538
    [Abstract] [Full Text] [Related]

  • 13. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases.
    Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A, Giordano C.
    Cancer; 2007 Sep 15; 110(6):1218-26. PubMed ID: 17685465
    [Abstract] [Full Text] [Related]

  • 14. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose.
    Hamatani K, Eguchi H, Ito R, Mukai M, Takahashi K, Taga M, Imai K, Cologne J, Soda M, Arihiro K, Fujihara M, Abe K, Hayashi T, Nakashima M, Sekine I, Yasui W, Hayashi Y, Nakachi K.
    Cancer Res; 2008 Sep 01; 68(17):7176-82. PubMed ID: 18757433
    [Abstract] [Full Text] [Related]

  • 15. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA.
    Cancer Res; 2003 Aug 01; 63(15):4561-7. PubMed ID: 12907632
    [Abstract] [Full Text] [Related]

  • 16. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
    Guerra A, Zeppa P, Bifulco M, Vitale M.
    Thyroid; 2014 Feb 01; 24(2):254-9. PubMed ID: 23806056
    [Abstract] [Full Text] [Related]

  • 17. Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma.
    Sheu SY, Grabellus F, Schwertheim S, Handke S, Worm K, Schmid KW.
    Horm Metab Res; 2009 Jun 01; 41(6):482-7. PubMed ID: 19370505
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
    Kondo T, Nakazawa T, Murata S, Kurebayashi J, Ezzat S, Asa SL, Katoh R.
    Hum Pathol; 2007 Dec 01; 38(12):1810-8. PubMed ID: 17714762
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.